CD19 and neoplasm: In addition, clinical data from patients with diffuse large B cell lymphoma receiving CD19-directed CAR-T cells demonstrated a correlation between elevated NK-like CAR-T signatures and therapeutic nonresponse with tumor progression (15, 60).